Prudential PLC bought a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 8,594 shares of the medical research company's stock, valued at approximately $483,000.
Several other institutional investors have also bought and sold shares of EXAS. Captrust Financial Advisors increased its holdings in Exact Sciences by 24.5% during the third quarter. Captrust Financial Advisors now owns 9,433 shares of the medical research company's stock worth $643,000 after buying an additional 1,854 shares during the last quarter. IHT Wealth Management LLC purchased a new stake in shares of Exact Sciences during the 3rd quarter worth approximately $305,000. Quantinno Capital Management LP purchased a new position in Exact Sciences in the third quarter valued at approximately $223,000. Stifel Financial Corp grew its holdings in Exact Sciences by 2.3% during the third quarter. Stifel Financial Corp now owns 80,961 shares of the medical research company's stock valued at $5,515,000 after purchasing an additional 1,825 shares during the period. Finally, Zacks Investment Management bought a new stake in shares of Exact Sciences in the third quarter valued at $2,083,000. Institutional investors own 88.82% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on EXAS shares. Royal Bank of Canada started coverage on shares of Exact Sciences in a research note on Thursday, March 13th. They issued a "sector perform" rating and a $52.00 target price for the company. Piper Sandler decreased their price objective on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Barclays reduced their target price on Exact Sciences from $65.00 to $55.00 and set an "overweight" rating for the company in a report on Thursday. Guggenheim reaffirmed a "buy" rating and set a $60.00 price objective on shares of Exact Sciences in a research note on Friday. Finally, Scotiabank raised their price target on shares of Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a report on Monday, February 24th. Two equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $69.25.
Get Our Latest Report on EXAS
Exact Sciences Stock Performance
Shares of EXAS stock traded up $0.28 during mid-day trading on Monday, reaching $44.73. 328,030 shares of the company's stock traded hands, compared to its average volume of 2,599,775. Exact Sciences Co. has a 12 month low of $39.97 and a 12 month high of $72.83. The firm has a 50 day moving average price of $46.95 and a two-hundred day moving average price of $55.72. The firm has a market capitalization of $8.31 billion, a PE ratio of -8.03 and a beta of 1.14. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.23. The firm had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. On average, research analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current year.
Exact Sciences Company Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
